Pharmaceuticals company Emcure Pharmaceuticals announced Q2FY26 results Revenue from operations at Rs 2,270 crore, up 13.4% YoY. EBITDA margins at 19.3% with EBITDA at Rs 439 crore up 15.2% YoY. PAT at Rs 251 crore, up 24.7% YoY. Domestic business sales at Rs 1,031 crore, up 10.6% YoY. International business sales at Rs 1,238 crore, up 15.8% YoY. Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: “Q2 saw strong performance across all our businesses. We continue to augment our portfolio in all our focus markets though in-licensing and inhouse developments. Novo Nordisk partnership positions us well in the fast-growing obesity segment and gives us an early entry enabling us to shape the market. We remained focus on delivering strong growth along with margin improvement in all our key businesses.” Result PDF
Conference Call with Emcure Pharmaceuticals Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Emcure Pharmaceuticals announced Q1FY26 results Revenue from operations at Rs 2,101 crore, up 15.7% YoY. EBITDA margins at 19.2% with EBITDA up 20.1% YoY. PAT at Rs 215 crore, up 41% YoY. Domestic business sales at Rs 995 crore, up 9.4% YoY. International business sales at Rs 1,106 crore, up 22.1% YoY. Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: “We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets though in-licensing and in-house development. The expanded Sanofi partnership positions us well in the fast growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins. ” Result PDF